[
    [
        {
            "time": "2018-03-15",
            "original_text": "Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes",
            "features": {
                "keywords": [
                    "FDA Advisory Committee",
                    "empagliflozin",
                    "Lilly",
                    "Boehringer Ingelheim",
                    "type 1 diabetes"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "n/a"
            },
            "scores": {
                "News_content": "Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug",
            "features": {
                "keywords": [
                    "FDA panel",
                    "voted against",
                    "diabetes drug",
                    "Lilly-Boehringer Ingelheim"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "n/a"
            },
            "scores": {
                "News_content": "FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]